Geographic Atrophy clinical trials

Explore recruiting geographic atrophy clinical trials.

Recruiting geographic atrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Geographic Atrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)

Hungary, Belgium, France, Austria, Latvia, Italy +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)

Czechia, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Germany, Portugal, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Spain, Netherlands, Italy, Czechia, France, Germany +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Romania

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMD)

Czechia, Hungary, Germany, Austria, Italy, Spain +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Geographic Atrophy trials by city

Geographic Atrophy in Toronto Geographic Atrophy in Vancouver Geographic Atrophy in Montreal Geographic Atrophy in Calgary Geographic Atrophy in Edmonton Geographic Atrophy in Ottawa Geographic Atrophy in Winnipeg Geographic Atrophy in Quebec City Geographic Atrophy in Hamilton Geographic Atrophy in Kitchener Geographic Atrophy in London Geographic Atrophy in Halifax Geographic Atrophy in New York Geographic Atrophy in Los Angeles Geographic Atrophy in Chicago Geographic Atrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease